文献速递血液透析通路

抗凝治疗与血液透析通路建立后通路相关伤口感染增加相关

Anticoagulation Therapy is Associated with Increased Access-related Wound Infections after Hemodialysis Access Creation.
PubMed 文献 · Ann Vasc Surg · 2021-10-20

基于VQI数据库2011至2019年27757例透析通路建立患者,评估抗凝治疗对通路结局的影响。抗凝组伤口感染率3.8%,无抗凝组2.3%(P<0.001),多因素分析示抗凝与伤口感染风险升高独立相关(OR 1.513,95%CI 1.160-1.973,P=0.002)。抗凝未显著影响6个月通路通畅率。

要点

  • 透析通路建立后使用抗凝的患者伤口感染风险显著升高(OR 1.513)。
  • 抗凝治疗未显著影响6个月通路通畅率。
  • 对抗凝患者应密切监测通路感染征象。

核心结论

  • 抗凝治疗与血液透析通路建立后伤口感染率升高相关,但未影响6个月内短期通路通畅率。

研究设计与样本

  • 回顾性队列研究,查询VQI数据库2011至2019年接受动静脉内瘘或人工血管移植的患者,仅纳入有术后抗凝状态数据者,共27757例。

主要发现

  • 抗凝组伤口感染率为3.8%,无抗凝组为2.3%(P<0.001)。
  • 6个月随访时,无抗凝组通畅率为85.7%,抗凝组为84.3%(P=0.044)。
  • 人工血管移植患者中,无抗凝组通畅率83.0%,抗凝组81.2%(P=0.106)。
  • 多因素分析显示抗凝使用与伤口感染风险升高相关(OR 1.513,95%CI 1.160-1.973,P=0.002)。
  • 抗凝使用未显著影响通路通畅率。

临床怎么用

  • 对透析通路建立后接受抗凝治疗的患者,应加强通路感染征象的监测。

局限性

  • 抗凝治疗的长期影响仍需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of anticoagulation therapy (AC) on hemodialysis access patency and related complications is not well defined. Patients on long-term or chronic AC due to their underlying comorbid conditions may be particularly susceptible to access-related bleeding and complications from repetitive cannulation. Our goal is to assess the effect of anticoagulation therapy on outcomes after access creation. METHODS: The Vascular Quality Initiative (VQI) database was queried for patients undergoing arteriovenous fistula (AVF) or graft (AVG) placement, from 2011 to 2019. Only patients with data on post-procedural AC status were included. Anticoagulation use was defined as patients on warfarin, dabigatran, or rivaroxaban after access creation at postoperative follow up. Demographic and procedural details were analyzed. Wound infection and patency rates at six months were assessed. Binomial logistic regression analysis was performed to assess the association of anticoagulation use with these outcomes. RESULTS: A total of 27,757 patients underwent access creation, with the majority undergoing AVF creation (78.8%). The average age was 61.4 years and 55.3% were male. 12.9% of patients were on postoperative AC. The wound infection rate was 2.3- 3.8% in the no AC and AC cohorts, respectively (P < 0.001). At six months follow-up, patency was 85.7- 84.3% in the no AC and AC cohorts, respectively (P = 0.044). Expectedly, grafts had lower patency rates compared to AVF; those within the no AC cohort had a patency of 83.0% compared to 81.2 % in those on AC (P = 0.106). On multivariable analysis, anticoagulation use was associated with a higher risk of wound infections (odds ratio [OR] 1.513, 95% confidence interval [CI] 1.160-1.973, P = 0.002). AC use did not significantly affect access patency. CONCLUSION: Anticoagulation therapy was associated with a higher rate of wound infections but did not affect short-term access patency within six-months. These patients warrant close surveillance of their access for signs of infection. Furthermore, long-term implications of anticoagulation needs further evaluation.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kumpfbeck A, Rockman CB, Jacobowitz GR, et al. Anticoagulation Therapy is Associated with Increased Access-related Wound Infections after Hemodialysis Access Creation. Ann Vasc Surg. 2021. PMID: 34687891. doi:10.1016/j.avsg.2021.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。